News & Updates

Early intratracheal budesonide in extremely preterm infants receiving surfactant for respiratory distress syndrome appears to be of little to no benefit in terms of survival free of bronchopulmonary dysplasia (BPD), according to a study.

Children with obesity face an increased risk of sleep-related breathing disorders, similar to those with Prader-Willi syndrome, as reported in a retrospective study.

More than 39 million people worldwide could die from antibiotic-resistant infections from 2025 to 2050 as the superbug crisis intensifies, according to a new global analysis of antimicrobial resistance.

Including adjuvant nivolumab as part of a perioperative regimen for resectable NSCLC further improves the EFS benefit vs including nivolumab in a neoadjuvant-only setting, as suggested by a patient-level data analysis of CheckMate 77T and CheckMate 816 investigating each modality separately

A second-generation robotic electromagnetic navigation (EMN) bronchoscopic platform combined with integrated digital tomosynthesis (DT) demonstrates acceptable safety and high diagnostic yield for small peripheral lung nodules, results of the first-in-human study have shown.

Treatment with aumolertinib significantly prolonged progression-free survival (PFS) compared with placebo in patients with unresectable stage III EGFR-mutated non-small cell lung cancer (NSCLC) who did not experience disease progression following chemoradiotherapy (CRT), according to a preplanned interim analysis of the phase III POLESTAR trial presented at WCLC 2024. 

The WHO and the UN call for increased testing for differential diagnosis and co-infections of COVID-19 and flu.^1,2

New drug applications approved by US FDA as of 16-31 October 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.